Venous thromboembolism associated with hip and knee arthroplasty: Current prophylactic practices and outcomes

D. N. Mohr, M. D. Silverstein, D. M. Ilstrup, J. A. Heit, B. F. Morrey

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Joint registry and hospital data bases for 5,024 total hip and total knee arthroplasties done between 1986 and 1988 at the Mayo Clinic were used to study prophylactic measures and frequency of symptomatic deep venous thrombosis and pulmonary embolism. In virtually all patients, graduated compression stockings were used, with or without another type of prophylaxis. Only 44 of 3,115 patients who underwent hip arthroplasty (1.4%) and 32 of 1,909 patients who underwent knee arthroplasty (1.7%) had definite or probable deep venous thrombosis or pulmonary embolism. Death definitely or possibly attributable to pulmonary embolism occurred in 11 patients who underwent hip arthroplasty (0.35%) and 1 patient who underwent knee arthroplasty (0.05%). Although patients with a history of deep venous thrombosis or pulmonary embolism were more likely to receive warfarin than were patients without such a history, the relative risk of symptomatic deep venous thrombosis or pulmonary embolism in patients who underwent hip arthroplasty and received warfarin postoperatively was approximately half that in patients who received other types of prophylaxis. The risk of death from pulmonary embolism was similarly diminished in the group that received warfarin. The lower rates of these complications in the patients who received warfarin support the prophylactic use of this agent after total hip arthroplasty.

Original languageEnglish (US)
Pages (from-to)861-870
Number of pages10
JournalMayo Clinic Proceedings
Volume67
Issue number9
StatePublished - 1992
Externally publishedYes

Fingerprint

Knee Replacement Arthroplasties
Venous Thromboembolism
Hip
Pulmonary Embolism
Warfarin
Venous Thrombosis
Arthroplasty
Compression Stockings
Registries
Joints
History
Databases

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Mohr, D. N., Silverstein, M. D., Ilstrup, D. M., Heit, J. A., & Morrey, B. F. (1992). Venous thromboembolism associated with hip and knee arthroplasty: Current prophylactic practices and outcomes. Mayo Clinic Proceedings, 67(9), 861-870.

Venous thromboembolism associated with hip and knee arthroplasty : Current prophylactic practices and outcomes. / Mohr, D. N.; Silverstein, M. D.; Ilstrup, D. M.; Heit, J. A.; Morrey, B. F.

In: Mayo Clinic Proceedings, Vol. 67, No. 9, 1992, p. 861-870.

Research output: Contribution to journalArticle

Mohr, DN, Silverstein, MD, Ilstrup, DM, Heit, JA & Morrey, BF 1992, 'Venous thromboembolism associated with hip and knee arthroplasty: Current prophylactic practices and outcomes', Mayo Clinic Proceedings, vol. 67, no. 9, pp. 861-870.
Mohr, D. N. ; Silverstein, M. D. ; Ilstrup, D. M. ; Heit, J. A. ; Morrey, B. F. / Venous thromboembolism associated with hip and knee arthroplasty : Current prophylactic practices and outcomes. In: Mayo Clinic Proceedings. 1992 ; Vol. 67, No. 9. pp. 861-870.
@article{a73b21cc72374437924d0846ba04d493,
title = "Venous thromboembolism associated with hip and knee arthroplasty: Current prophylactic practices and outcomes",
abstract = "Joint registry and hospital data bases for 5,024 total hip and total knee arthroplasties done between 1986 and 1988 at the Mayo Clinic were used to study prophylactic measures and frequency of symptomatic deep venous thrombosis and pulmonary embolism. In virtually all patients, graduated compression stockings were used, with or without another type of prophylaxis. Only 44 of 3,115 patients who underwent hip arthroplasty (1.4{\%}) and 32 of 1,909 patients who underwent knee arthroplasty (1.7{\%}) had definite or probable deep venous thrombosis or pulmonary embolism. Death definitely or possibly attributable to pulmonary embolism occurred in 11 patients who underwent hip arthroplasty (0.35{\%}) and 1 patient who underwent knee arthroplasty (0.05{\%}). Although patients with a history of deep venous thrombosis or pulmonary embolism were more likely to receive warfarin than were patients without such a history, the relative risk of symptomatic deep venous thrombosis or pulmonary embolism in patients who underwent hip arthroplasty and received warfarin postoperatively was approximately half that in patients who received other types of prophylaxis. The risk of death from pulmonary embolism was similarly diminished in the group that received warfarin. The lower rates of these complications in the patients who received warfarin support the prophylactic use of this agent after total hip arthroplasty.",
author = "Mohr, {D. N.} and Silverstein, {M. D.} and Ilstrup, {D. M.} and Heit, {J. A.} and Morrey, {B. F.}",
year = "1992",
language = "English (US)",
volume = "67",
pages = "861--870",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "9",

}

TY - JOUR

T1 - Venous thromboembolism associated with hip and knee arthroplasty

T2 - Current prophylactic practices and outcomes

AU - Mohr, D. N.

AU - Silverstein, M. D.

AU - Ilstrup, D. M.

AU - Heit, J. A.

AU - Morrey, B. F.

PY - 1992

Y1 - 1992

N2 - Joint registry and hospital data bases for 5,024 total hip and total knee arthroplasties done between 1986 and 1988 at the Mayo Clinic were used to study prophylactic measures and frequency of symptomatic deep venous thrombosis and pulmonary embolism. In virtually all patients, graduated compression stockings were used, with or without another type of prophylaxis. Only 44 of 3,115 patients who underwent hip arthroplasty (1.4%) and 32 of 1,909 patients who underwent knee arthroplasty (1.7%) had definite or probable deep venous thrombosis or pulmonary embolism. Death definitely or possibly attributable to pulmonary embolism occurred in 11 patients who underwent hip arthroplasty (0.35%) and 1 patient who underwent knee arthroplasty (0.05%). Although patients with a history of deep venous thrombosis or pulmonary embolism were more likely to receive warfarin than were patients without such a history, the relative risk of symptomatic deep venous thrombosis or pulmonary embolism in patients who underwent hip arthroplasty and received warfarin postoperatively was approximately half that in patients who received other types of prophylaxis. The risk of death from pulmonary embolism was similarly diminished in the group that received warfarin. The lower rates of these complications in the patients who received warfarin support the prophylactic use of this agent after total hip arthroplasty.

AB - Joint registry and hospital data bases for 5,024 total hip and total knee arthroplasties done between 1986 and 1988 at the Mayo Clinic were used to study prophylactic measures and frequency of symptomatic deep venous thrombosis and pulmonary embolism. In virtually all patients, graduated compression stockings were used, with or without another type of prophylaxis. Only 44 of 3,115 patients who underwent hip arthroplasty (1.4%) and 32 of 1,909 patients who underwent knee arthroplasty (1.7%) had definite or probable deep venous thrombosis or pulmonary embolism. Death definitely or possibly attributable to pulmonary embolism occurred in 11 patients who underwent hip arthroplasty (0.35%) and 1 patient who underwent knee arthroplasty (0.05%). Although patients with a history of deep venous thrombosis or pulmonary embolism were more likely to receive warfarin than were patients without such a history, the relative risk of symptomatic deep venous thrombosis or pulmonary embolism in patients who underwent hip arthroplasty and received warfarin postoperatively was approximately half that in patients who received other types of prophylaxis. The risk of death from pulmonary embolism was similarly diminished in the group that received warfarin. The lower rates of these complications in the patients who received warfarin support the prophylactic use of this agent after total hip arthroplasty.

UR - http://www.scopus.com/inward/record.url?scp=0026662743&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026662743&partnerID=8YFLogxK

M3 - Article

C2 - 1434931

AN - SCOPUS:0026662743

VL - 67

SP - 861

EP - 870

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 9

ER -